Last reviewed · How we verify

Centro de Atencion e Investigacion Medica — Portfolio Competitive Intelligence Brief

Centro de Atencion e Investigacion Medica pipeline: 5 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Rivotril® Rivotril® marketed
Theralite® Theralite® marketed
Actilitio® Actilitio® marketed PD-1 inhibitor PD-1 Oncology
Revolade® Revolade® marketed Thrombopoietin receptor agonist TPO receptor (TPOR/MPL) Hematology
Eltrombopag (EPAG) Eltrombopag (EPAG) marketed Thrombopoietin receptor agonist TPO receptor (c-Mpl) Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Amgen · 2 shared drug classes
  2. GlaxoSmithKline · 2 shared drug classes
  3. Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
  4. ATGC Co., Ltd. · 1 shared drug class
  5. Akeso · 1 shared drug class
  6. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  7. Asahi Kasei Pharma Corporation · 1 shared drug class
  8. Addpharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Centro de Atencion e Investigacion Medica:

Cite this brief

Drug Landscape (2026). Centro de Atencion e Investigacion Medica — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centro-de-atencion-e-investigacion-medica. Accessed 2026-05-18.

Related